LF LFWD Lifeward Ltd. Loading... : Investor Sentiment and Bull/Bear Views

The author claims LFWD is a turnaround priced for survival at a ~$20M market cap with ~$15M cash and a very low float, so a revealed path to profitability could cause a snowball re-rating. The mechanism is that growth capital funds sales, unlocking $5.6M and potentially up to $47M from Oramed, which supports profitability and then a pipeline including the Skelable exoskeleton (expected next year) and oral insulin in Phase 2 FDA trials. The main stated risk is that this is a very small-cap, low-volume, low-float stock, plus execution/funding uncertainty. Time horizon is medium-term, with Skelable expected next year and profitability described as closer than expected.

The author argues Lifeward is a $7.8m market cap turnaround led by CEO Mark Grant, who joined June 2025 with a MedTech track record including 25 years at Medtronic and skill at securing insurance coverage. UnitedHealthCare, Humana and Aetna now cover Lifeward's exoskeleton product at roughly $100k average cost, and the author expects the March 6 earnings call to give good forward guidance on increased sales. The improved AlterG Neo product is more cost-effective with wider market penetration, and Oramed is partnering to launch a first oral insulin with a reworked Phase 3 trial later this year or early 2027; passing that trial is described as a high-risk, high-reward lottery.